OncoSec Medical Inc (ONCSQ)

[chickpea598]

Merck and Bristol Myers reporting positive results this weekend with Merck coming out ahead in Bladder Cancer (25% ORR vs. 19% for Bristol). Bladder cancer is another indication that Immunopulse could be pared with Keytruda. Merck could enhance their entire Keytuda franchise with the addition of immunopulse IL-12 for multiple indications.

Keep the faith here folks. My advice to all investors in Oncosec is to stretch your timeline out as much as needed and don't panic sell this. The market will eventually give Oncosec the respect they deserve.

With the deep pockets Merck has, they could start as many fast track combo studies they want for multiple cancer indications with immunopulse IL-12. Keytruda is the best pipeline drug they have and they will need to milk it for all they can. Money will only continue to spread out in search of they best indications......and I believe Oncosec will benefit once we get the combo results in the next few months.